PRCT vs. AXNX, IRTC, TNDM, NARI, ICUI, NVCR, IART, INSP, MMSI, and HAE
Should you be buying PROCEPT BioRobotics stock or one of its competitors? The main competitors of PROCEPT BioRobotics include Axonics (AXNX), iRhythm Technologies (IRTC), Tandem Diabetes Care (TNDM), Inari Medical (NARI), ICU Medical (ICUI), NovoCure (NVCR), Integra LifeSciences (IART), Inspire Medical Systems (INSP), Merit Medical Systems (MMSI), and Haemonetics (HAE). These companies are all part of the "surgical & medical instruments" industry.
Axonics (NASDAQ:AXNX) and PROCEPT BioRobotics (NASDAQ:PRCT) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, community ranking, institutional ownership, media sentiment, analyst recommendations, valuation and risk.
Axonics received 146 more outperform votes than PROCEPT BioRobotics when rated by MarketBeat users. Likewise, 66.92% of users gave Axonics an outperform vote while only 62.22% of users gave PROCEPT BioRobotics an outperform vote.
In the previous week, Axonics and Axonics both had 5 articles in the media. PROCEPT BioRobotics' average media sentiment score of 1.22 beat Axonics' score of 0.79 indicating that Axonics is being referred to more favorably in the media.
Axonics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.
99.5% of Axonics shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 1.9% of Axonics shares are owned by insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Axonics currently has a consensus price target of $70.73, indicating a potential upside of 4.70%. PROCEPT BioRobotics has a consensus price target of $61.20, indicating a potential downside of 10.13%. Given PROCEPT BioRobotics' higher probable upside, research analysts clearly believe Axonics is more favorable than PROCEPT BioRobotics.
Axonics has a net margin of -4.12% compared to Axonics' net margin of -66.12%. PROCEPT BioRobotics' return on equity of -2.58% beat Axonics' return on equity.
Axonics has higher revenue and earnings than PROCEPT BioRobotics. Axonics is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.
Summary
Axonics beats PROCEPT BioRobotics on 11 of the 17 factors compared between the two stocks.
Get PROCEPT BioRobotics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PROCEPT BioRobotics Competitors List
Related Companies and Tools
